WILMINGTON,aaiPharma has completed the purchase of four pain products and related assets for almost $102 million from Elan Corp. of Dublin, Ireland.
These products include the rights to Roxicodone tablets and oral solution, Oramorph SR tablets, Roxanol and Duraclon.
Elan said the deal was worth $101.8 million, comprising a cash payment to Elan of $50.4 million and the assumption by aaiPharma of $51.4 million of Elan’s product related payments.
aaiPharma, based in Wilmington, says it plans to formally launch the products with a focused sales force promotion in mid-January 2004.
aaiPharma: www.aaipharma.com
